Braasch Biotech LLC is pioneering a new class of biopharmaceutical vaccines aimed at addressing significant health challenges in both human and animal populations. The company's innovative Cross Platform Utilization of Vaccination (CPUV™) technology represents a transformative approach in vaccinology, focusing on the development of second-generation somatostatin-based immunopharmaceutical vaccines. These vaccines target critical health issues such as human obesity, Type 2 diabetes, and growth hormone deficiencies in children, as well as enhancing livestock productivity through specific vaccines designed for dairy cows and swine. The company has successfully established proof-of-concept in various models, indicating the potential effectiveness of their vaccine products.

In addition to their focus on human health, Braasch Biotech is also addressing obesity in companion animals through targeted vaccines for dogs, cats, and older horses. The company has made significant strides in intellectual property development, securing patents across multiple regions, including the United States, Europe, and Asia, which bolsters their position in the competitive biopharmaceutical landscape. With a diversified pipeline of products and a commitment to innovative solutions, Braasch Biotech is poised to make a substantial impact on healthcare markets by providing effective treatment alternatives that minimize the need for traditional drug therapies.

United States

Privately owned biopharmaceutical company pioneering the use of anti-somatostatin vaccine use. Our products (under the trademark Somatovac) have been used for treatment of metaboloic conditions, such as obesity, and productivity enhancement (livestock). Braasch has a US and international patent portfolio for our core technology (protein), application as vaccines, adjuvants and metabolic adjustment.

Braasch Biotech LLC

Company Details